Literature DB >> 19440670

The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells.

Cornelia Czembirek1, Christina Eder-Czembirek, Boban M Erovic, Dritan Turhani, Andreas Spittler, Edgar Selzer, Richard Pötter, Dietmar Thurnher.   

Abstract

BACKGROUND: No data are available on the effects of the cyclooxygenase-2 (COX-2) inhibitor nimesulide in combination with irradiation on the survival of head-and-neck carcinoma cells.
MATERIAL AND METHODS: Two head-and-neck carcinoma cell lines (SCC9 and SCC25) were treated with nimesulide (50-600 microM) and irradiated concomitantly or sequentially. Early effects on cell survival were investigated by counting cell numbers, long-term effects by colony-forming assays. Cell-cycle effects were analyzed 24-72 h after treatment with nimesulide by flow cytometry.
RESULTS: Unexpectedly, nimesulide solely inhibited cell proliferation without affecting colony-forming ability. In addition, no evidence for a radiosensitizing effect of nimesulide in short-term assays was seen. Nimesulide alone had no effect on clonogenic survival alone or in combination with radiation.
CONCLUSION: Nimesulide differentially affects cell proliferation and clonogenic survival and may decrease the efficacy of radiotherapy. Short-term assays to assess tumor growth may not correctly predict the clinically relevant long-term effect of COX-2 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19440670     DOI: 10.1007/s00066-009-1929-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  48 in total

Review 1.  Cyclooxygenase-2: a therapeutic target.

Authors:  Marco E Turini; Raymond N DuBois
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

Review 2.  Barrett's esophagus: chemoprevention.

Authors:  Rhonda F Souza; Stuart J Spechler
Journal:  Gastrointest Endosc Clin N Am       Date:  2003-07

3.  [Does aspirin reduce the risk of colorectal polyps and cancer?].

Authors:  R Sauer
Journal:  Strahlenther Onkol       Date:  1994-02       Impact factor: 3.621

4.  The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.

Authors:  Helena A Minter; John W Eveson; Suzanne Huntley; Douglas J E Elder; Angela Hague
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

Review 5.  [Simultaneous radiochemotherapy].

Authors:  J Dunst; R Sauer
Journal:  Strahlenther Onkol       Date:  1993-04       Impact factor: 3.621

6.  Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin.

Authors:  Y Furuta; E R Hall; S Sanduja; T Barkley; L Milas
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

7.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.

Authors:  X H Liu; S Yao; A Kirschenbaum; A C Levine
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

8.  Celecoxib activates a novel mitochondrial apoptosis signaling pathway.

Authors:  Verena Jendrossek; René Handrick; Claus Belka
Journal:  FASEB J       Date:  2003-06-17       Impact factor: 5.191

9.  Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.

Authors:  Min Yao; Stacia Kargman; Eugene C Lam; Colleen R Kelly; Yaxin Zheng; Pauline Luk; Elizabeth Kwong; Jilly F Evans; M Michael Wolfe
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

10.  Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.

Authors:  D J Elder; D E Halton; A Hague; C Paraskeva
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

View more
  5 in total

1.  Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines.

Authors:  Christina Eder-Czembirek; Boban M Erovic; Cornelia Czembirek; Markus Brunner; Edgar Selzer; Richard Pötter; Dietmar Thurnher
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

2.  Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.

Authors:  Frank Michael Klenke; Amir Abdollahi; Marc Bischof; Martha-Maria Gebhard; Volker Ewerbeck; Peter E Huber; Axel Sckell
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

3.  The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.

Authors:  Cyril Sobolewski; Claudia Cerella; Mario Dicato; Lina Ghibelli; Marc Diederich
Journal:  Int J Cell Biol       Date:  2010-03-17

Review 4.  Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy-A Hypothesis-Driven Review.

Authors:  Markus Laube; Torsten Kniess; Jens Pietzsch
Journal:  Antioxidants (Basel)       Date:  2016-04-19

5.  Synthesis and Different Effects of Biotinylated PAMAM G3 Dendrimer Substituted with Nimesulide in Human Normal Fibroblasts and Squamous Carcinoma Cells.

Authors:  Łukasz Uram; Aleksandra Filipowicz-Rachwał; Maria Misiorek; Aleksandra Winiarz; Elżbieta Wałajtys-Rode; Stanisław Wołowiec
Journal:  Biomolecules       Date:  2019-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.